190 related articles for article (PubMed ID: 9781152)
1. [Prognostic factors and treatment of advanced Hodgkin's disease].
Fermé C
Rev Prat; 1998 May; 48(10):1082-6. PubMed ID: 9781152
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic factors and treatment of localized Hodgkin's disease].
Carde P; Cosset JM
Rev Prat; 1998 May; 48(10):1075-81. PubMed ID: 9781151
[TBL] [Abstract][Full Text] [Related]
3. Treatment strategies for Hodgkin's disease.
Bonadonna G; Santoro A; Viviani S; Valagussa P
Semin Hematol; 1988 Apr; 25(2 Suppl 2):51-7. PubMed ID: 3041600
[TBL] [Abstract][Full Text] [Related]
4. [Clinical aspects and primary therapy of Hodgkin's lymphomas].
Sieber M; Tesch H; Diehl V
Praxis (Bern 1994); 1996 Mar; 85(12):364-70. PubMed ID: 8643899
[TBL] [Abstract][Full Text] [Related]
5. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
[TBL] [Abstract][Full Text] [Related]
6. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of resistant forms and recurrence of Hodgkin's disease].
Diviné M; Reyes F
Rev Prat; 1998 May; 48(10):1087-91. PubMed ID: 9781153
[TBL] [Abstract][Full Text] [Related]
8. The contribution of clinical trials to the treatment of patients with early stages of Hodgkin's disease.
Tubiana M; Cosset JM; Carde P; Henry-Amar M; Hayat M; Amiel JL
Drugs Exp Clin Res; 1986; 12(1-3):105-12. PubMed ID: 3732047
[TBL] [Abstract][Full Text] [Related]
9. State-of-the-art therapeutics: Hodgkin's lymphoma.
Connors JM
J Clin Oncol; 2005 Sep; 23(26):6400-8. PubMed ID: 16155026
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic strategies of Hodgkin's disease].
Lathan B; Pfreundschuh M; Diehl V
Internist (Berl); 1993 Feb; 34(2):146-54. PubMed ID: 8454428
[No Abstract] [Full Text] [Related]
12. Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution.
Smolewski P; Robak T; Krykowski E; Blasiñska-Morawiec M; Niewiadomska H; Pluzanska A; Chmielowska E; Zambrano O
Clin Cancer Res; 2000 Mar; 6(3):1150-60. PubMed ID: 10741746
[TBL] [Abstract][Full Text] [Related]
13. Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy.
Vigouroux S; Milpied N; Andrieu JM; Colonna P; Ifrah N; Colombat P; Desablens B; Abgrall JF; Casassus P; Guilhot F; Briere J; Le Mevel A; Moreau P; Mechinaud F; Mahe B; Morineau N; Vigier M; Rapp MJ; Harousseau JL
Bone Marrow Transplant; 2002 May; 29(10):833-42. PubMed ID: 12058233
[TBL] [Abstract][Full Text] [Related]
14. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
Akhtar S; El Weshi A; Abdelsalam M; Hussaini H; Janabi I; Rahal M; Maghfoor I
Bone Marrow Transplant; 2007 Oct; 40(7):651-8. PubMed ID: 17660837
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy.
Smith RS; Chen Q; Hudson MM; Link MP; Kun L; Weinstein H; Billett A; Marcus KJ; Tarbell NJ; Donaldson SS
J Clin Oncol; 2003 May; 21(10):2026-33. PubMed ID: 12743158
[TBL] [Abstract][Full Text] [Related]
16. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.
Bonadonna G; Bonfante V; Viviani S; Di Russo A; Villani F; Valagussa P
J Clin Oncol; 2004 Jul; 22(14):2835-41. PubMed ID: 15199092
[TBL] [Abstract][Full Text] [Related]
17. Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation.
Sénécal D; Jais JP; Desablens B; Berthou C; Casassus P; Moles MP; Delwail V; Gastinne T; Colonna P; Andrieu JM
Cancer; 2008 Feb; 112(4):846-55. PubMed ID: 18072259
[TBL] [Abstract][Full Text] [Related]
18. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY
Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021
[TBL] [Abstract][Full Text] [Related]
19. Management of stage I and II Hodgkin's disease.
Farah R; Weichselbaum RR
Hematol Oncol Clin North Am; 1989 Jun; 3(2):253-63. PubMed ID: 2663826
[TBL] [Abstract][Full Text] [Related]
20. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
